Five patent takeaways from Pfizer’s $43 billion Seagen buyout

Five patent takeaways from Pfizer’s $43 billion Seagen buyout

The takeover of the biopharma innovator is the largest pharma sector deal since 2019

Unlock unlimited access to all IAM content